Advertisement

Topics

STAT Plus: Novo Nordisk to pay $58 million for not complying with an FDA program

18:05 EDT 5 Sep 2017 | STAT

Novo Nordisk agreed to pay $58 million to settle allegations it failed to adequately alert doctors a diabetes drug may be associated with thyroid cancer.

Original Article: STAT Plus: Novo Nordisk to pay $58 million for not complying with an FDA program

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Novo Nordisk to pay $58 million for not complying with an FDA program"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...